Program
darolutamide
Also written as “Darolutamide”, “Darolutamide (Nubeqa, BAY1841788)” and “Darolutamide (BAY1841788, Nubeqa)”.
Its studies are mostly in Prostatic Neoplasms · Prostatic Neoplasms, Castration-Resistant · Bulbo-Spinal Atrophy, X-Linked · Neoplasms · Neoplasm Metastasis, led by 2 companies.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Bayer | 164 open or running | phase 4since Apr 21, 2022 | Jul 22, 2014 | Jul 30, 2027phase 3 · NCT05794906 |
| Orion Corporation, Orion Pharma | 40 open or running | phase 2since Mar 7, 2011 | Mar 7, 2011 | none ahead |
Also a collaborator on its studies: Keenova Therapeutics.
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
Before these, 7 studies since Mar 7, 2011.
- Jun 6, 2016Phase 3 study in Metastatic Hormone-sensitive Prostate CancerBayer · NCT02799602 · 1,306 enrolled · United States, Australia, Belgium and more
- Aug 29, 2016Phase 1 study in Hepatic InsufficiencyBayer · NCT02894385 · 29 enrolled · Germany
- Feb 8, 2017Phase 1 study in Biological AvailabilityBayer · NCT03048110 · 15 enrolled · Germany
- Jul 26, 2017Phase 1 study in Prostatic NeoplasmsBayer · NCT03237416 · 15 enrolled · Germany
- Oct 10, 2018Phase 1 study in Cerebrovascular CirculationBayer · NCT03704519 · 26 enrolled · United Kingdom
- Oct 21, 2019Phase 2 study in Prostatic Neoplasms, Castration-ResistantBayer · NCT04157088 · 30 enrolled · United States
- Jul 7, 2020Phase 3 study in NeoplasmsBayer · NCT04464226 · 774 enrolled · United States, Argentina, Australia and more
- Jan 29, 2021Phase 3 study in Prostatic NeoplasmsBayer · NCT04736199 · 669 enrolled · Australia, Brazil, Canada and more
- Sep 17, 2021Phase 2 study in Prostatic NeoplasmsBayer · NCT05059236 · 223 enrolled · United States
- Apr 21, 2022Phase 4 study in Prostatic NeoplasmsBayer · NCT05348876 · 50 planned · India
- Aug 31, 2022Phase 2 study in Biochemically Recurrent Prostate CancerBayer · NCT05526248 · 28 enrolled · United States
- Mar 21, 2023Phase 3 study in Biochemically Recurrent Prostate CancerBayer · NCT05794906 · 985 enrolled · United States, Australia, Austria and more
- Feb 12, 2026Phase 2 study in High-risk Localized Prostate CancerBayer · NCT07450599 · 250 planned · China
- Nov 5, 2026Primary completion moved from 2027-04-29 to 2027-12-30Date moved laterphase 4 · +8 months · NCT05348876
Ahead
- Jul 30, 2027Primary completion: phase 3 study in Biochemically Recurrent Prostate CancerBayer · NCT05794906
- Dec 30, 2027Primary completion: phase 4 study in Prostatic NeoplasmsBayer · NCT05348876
- Jun 26, 2028Primary completion: phase 3 study in NeoplasmsBayer · NCT04464226
- Oct 15, 2028Primary completion: phase 2 study in High-risk Localized Prostate CancerBayer · NCT07450599
TargetBeta
“A formulation containing an androgen receptor (AR) antagonist ”NCIt, by rule
“Androgen Receptor antagonist”ChEMBL 37, by rule
Other programs on AR
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| enzalutamiderule | Astellas Pharma | phase 4 | 69 |
| apalutamiderule | Johnson & Johnson | phase 4 | 31 |
| Clascoteronerule | cassiopea-spa | phase 4 | 19 |
| ostarinerule | gtx | phase 3 | 15 |
| rezvilutamiderule | Jiangsu HengRui Medicine | phase 3 | 13 |
| dezandrodegrule | Bristol-Myers Squibb | phase 3 | 5 |
| Cyproterone Acetaterule | Eurofarma Laboratorios | phase 3 | 4 |
| Androgen Receptor-targeting Regulated Induced Proximity Targeting Chimera HLD-0915 | Johnson & Johnson | phase 3 | 3 |
| HRS-5041 | Jiangsu HengRui Medicine | phase 2 | 6 |
| luxdegalutamide | Novartis | phase 2 | 3 |
| luxdegalutamide | Novartis | phase 2 | 2 |
| Androgen Receptor Degrader AZD9750rule | AstraZeneca | phase 2 | 1 |
Studies
All 20 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Led by | Primary completion | Size |
|---|---|---|---|---|---|
| NCT07450599High-risk Localized Prostate Cancer · China | 2 | Recruiting | Bayer | Oct 15, 2028 | 250 |
| NCT05794906Biochemically Recurrent Prostate Cancer · United States, Australia, Austria and more | 3 | Active, not recruiting | Bayer | Jul 30, 2027 | 985 |
| NCT05526248Biochemically Recurrent Prostate Cancer · United States | 2 | Completed | Bayer | Aug 20, 2024 | 28 |
| NCT05348876Prostatic Neoplasms · India | 4 | Recruiting | Bayer | Dec 30, 2027 | 50 |
| NCT05059236Prostatic Neoplasms · United States | 2 | Completed | Bayer | May 30, 2025 | 223 |
| NCT04736199Prostatic Neoplasms · Australia, Brazil, Canada and more | 3 | Completed | Bayer | Jun 7, 2024 | 669 |
| NCT04464226Neoplasms · United States, Argentina, Australia and more | 3 | Active, not recruiting | Bayer | Jun 26, 2028 | 774 |
| NCT04157088Prostatic Neoplasms, Castration-Resistant · United States | 2 | Terminated | Bayer | Jul 8, 2022 | 30 |
| NCT03704519Cerebrovascular Circulation · United Kingdom | 1 | Completed | Bayer | Oct 1, 2019 | 26 |
| NCT03237416Prostatic Neoplasms · Germany | 1 | Completed | Bayer | Oct 5, 2017 | 15 |
| NCT03048110Biological Availability · Germany | 1 | Completed | Bayer | May 4, 2017 | 15 |
| NCT02894385Hepatic Insufficiency · Germany | 1 | Completed | Bayer | Apr 10, 2017 | 29 |
| NCT02799602Metastatic Hormone-sensitive Prostate Cancer · United States, Australia, Belgium and more | 3 | Completed | Bayer | Oct 25, 2021 | 1,306 |
| NCT02671097Healthy Volunteers · Germany | 1 | Completed | Bayer | May 2016 | 30 |
| NCT02418650Healthy · United Kingdom | 1 | Completed | Orion Corporation, Orion Pharma | May 2015 | 12 |
| NCT02363855Prostatic Neoplasms · Japan | 1 | Completed | Bayer | Nov 19, 2015 | 9 |
| NCT02200614Prostate Cancer Non-Metastatic · United States, Argentina, Australia and more | 3 | Completed | Bayer | Sep 3, 2018 | 1,509 |
| NCT01784757Prostatic Neoplasms · Latvia | 1 | Completed | Orion Corporation, Orion Pharma | Aug 2013 | 30 |
| NCT01429064Prostatic Neoplasms · United States, Czech Republic, Estonia and more | 2 | Completed | Orion Corporation, Orion Pharma | Nov 2015 | 76 |
| NCT01317641Prostatic Neoplasms · United States, Czech Republic, Estonia and more | 2 | Completed | Orion Corporation, Orion Pharma | Jul 2013 | 136 |
How it is read
Names in the registry
- “Darolutamide”, 6 entries
- “Darolutamide (Nubeqa, BAY1841788)”, 5 entries
- “Darolutamide (BAY1841788, Nubeqa)”, 2 entries
- “BAY1841788 (ODM-201)”, 2 entries
- “ODM-201”, 2 entries
Conditions, from the studies’ own filings
- Prostatic Neoplasms, 15 studies
- Prostatic Neoplasms, Castration-Resistant, 2 studies
- Bulbo-Spinal Atrophy, X-Linked, 1 study
- Neoplasms, 1 study
- Neoplasm Metastasis, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.